Bipolar affective disorders are common and frequently debilitating mental illnesses. Diagnostic criteria mean they are defined by the presence of pathological mood elevation, but research shows greater disease burden is inflicted by depressive phases (bipolar depression) both in terms of duration and impact of symptoms. Despite this there is consistent evidence for the underdiagnosis of bipolar depression and its misdiagnosis as a unipolar disorder, with significant subsequent impact on medication management. There is currently less robust evidence for the appropriate pharmacological approach in such individuals than in unipolar depression, and fewer guidelines for clinicians. Despite this there is clear and growing evidence that 'treatment as usual' of depressive symptomatology is ineffective at best, harmful at worst, and that there is little role for the use of antidepressants. Both mood stabilizers and antipsychotics demonstrate efficacy, and whilst there are emerging data on intraclass differences, more research is needed, particularly concerning bipolar II disorder. Present treatment strategies are limited by insufficient large randomized control trials, an inadequate understanding of the neuropathology of bipolar illnesses and a lack of tailored medications. Better clinical training, understanding and recognition of this common condition are essential.
Introduction
Bipolar affective disorders (BPADs) are complex mental illnesses that are frequently severe and chronic, and constitute a significant cause of disability and premature death [Nierenberg, 2008; Belmaker, 2007; Sachs et al. 2007; Bauer and Pfennig, 2005; Calabrese et al. 2005; Frye, 2011; Judd et al. 2003 Judd et al. , 2002 . The lifetime risk of at least one suicide attempt ranges from 25% to 50% [Bowden, 2005; Calabrese et al. 2005; Dalton et al. 2003; Tondo et al. 2003; Inskip et al. 1998 ], which is clearly higher than the typically cited 15% lifetime rate reported for people with major unipolar depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, ). Figures on the incidence of BPADs vary depending on the criteria used and the inclusion of bipolar II disorder and subthreshold populations, but typically range from 1% to 4% [Suppes et al. 2010; Merikangas et al. 2007; Vacheron-Trystram et al. 2004; Akiskal et al. 2003; Judd et al. 2003 Judd et al. , 2002 Angst, 1998 ].
Bipolar disorders, as the name suggests, manifest with two different spectra (or 'poles') of symptoms: depressive and manic (or hypomanic). The depressive phases (bipolar depression) resemble the classical description of a unipolar depressive disorder, with core symptoms of low mood, anhedonia and low energy levels as well as any of the other typical somatic and biological symptoms, such as altered sleep, appetite and libido, early morning wakening, depressive ruminations, feelings of guilt, and suicidality [DSM-IV, 2000; WHO, 2004] . Bipolar disorders are further classified into at least two categories: bipolar I and bipolar II; the nature and significance of other subdiagnoses is debated, but consensus about a bipolar spectrum is emerging. Bipolar I is the classic description of an alternating mood disorder with intermittent protracted episodes of depression and pathological mood elevation. Bipolar II is similarly characterized by pathological mood variation, but depressive episodes grossly dominate the clinical picture and periods of mood elevation are typically very brief (lasting hours to days), self-limiting and nonpsychotic.
Indeed, such symptoms can be so mild that they are frequently missed by patients and relatives as well as clinicians, often being regarded as just a relative, and positive, change in mood in relation to debilitating depression [Smith et al. 2010; Bauer and Pfennig, 2005] . The Zurich criteria [Angst et al. 2003 ], which are based on a 20year prospective community cohort study, highlight that the nature of the symptoms is of more relevance than their duration, and importance should be attributed to even very brief 'highs' once the core criteria of pathological mood elevation are met.
Although bipolar disorder is defined by the occurrence of mania and hypomania and is frequently conceptualized in terms of episodic mood elevation by clinicians, depressive episodes and symptoms tend to dominate the course of the illness: they occur more frequently, last longer and lead to a greater proportion of the psychosocial disability [Bond et al. 2010; Frye, 2011; Sidor and Macqueen, 2010; Van Lieshout and Macqueen, 2010; Geddes et al. 2009; Ghaemi et al. 2008; Bowden, 2005; Gijsman et al. 2004; Judd et al. 2002] . Work by Judd and colleagues suggests that, in bipolar I, patients are well or asymptomatic for 53% of the time, and that during the time they are unwell manic or hypomanic states only account for 20% of the time (mixed states 13%, depressive states 67%) [Judd et al. 2003 [Judd et al. , 2002 . This is even starker in bipolar II, in which during the 54% of the time patients are unwell hypomanic states only account for 2% of the illness and depression accounts for 94% (mixed states taking up the remaining 4%). Kessler and colleagues highlighted the fact that work days lost per ill worker per year among patients with BPAD was greater than among those with unipolar major depression; the difference was driven primarily by recurrent depression, not mania [Kessler et al. 2006 ]. Furthermore, it typically takes longer to achieve remission in depressive than in manic phases of illness, although mixed/ cycling individuals take longer again [Berk et al. 2005] .
With such figures it is apparent that, in bipolar disorders depression is the major problem, but its accurate diagnosis and appropriate management, even when identified, has been suggested to be one of the most challenging fields in contemporary psychiatry, with a dearth of established guidelines and licensed treatments [Fountoulakis, 2010; Frye, 2011; Smith et al. 2011; Suppes et al. 2010] .
The clinical problems

Bipolar depression is clinically missed
Recognizing bipolar depression is a major challenge to most clinicians [Fountoulakis, 2010; Smith et al. 2011; Suppes et al. 2010; Sachs, 1996] . In addition to the reasons common to all mental illness (symptom overlap with other psychiatric disorders; comorbidity and substance misuse; potential lack of insight, nonengagement, nondisclosure and stigma), bipolar depression has the unique diagnostic difficulty of typically being clinically very similar to unipolar depression on mental state assessment. Patient presentation and emphasis might be most concerned with the current depressive symptomatology and focused on its alleviation, potentially forgetting, ignoring or downplaying previous manic or hypomanic symptoms; this may be even more likely in bipolar II disorder. Retrospective analysis showed that between 25% and 50% [Angst, 2007; Hirschfeld et al. 2003; Ghaemi et al. 1999] of those with bipolar depression were initially diagnosed with a unipolar illness, and the first presentation of BPAD was more likely to be with a depressive illness [Forty et al. 2008 ]. Ghaemi and colleagues showed a mean interval of 7.5 years to correct diagnosis [Ghaemi et al. 1999] , whilst analysis of the National Depression and Manic Depression Survey in 1994 and 2000 showed that patients were typically symptomatic for more than 10 years before the correct diagnosis was made [Hirschfeld et al. 2003; Lish et al. 1994 ]. Delays in recognizing and diagnosing bipolar depression can prevent appropriate treatment, with serious potential implications [Berk et al. 2006; Bowden, 2005] including impaired social development, harmful effects from inappropriate treatment [Ghaemi et al. 2004 ] and possibly a higher risk of suicide [Baldessarini et al. 2006 ].
Although bipolar depression is very similar to unipolar depression, factors in the history and presentation might indicate the possibility of bipolar depression. Demographically, those with bipolar depression are more likely to have an earlier age of onset, a greater number of illness episodes, a positive family history of a bipolar illness and a more treatment-refractory and severe illness history [Smith et al. 2011; Forty et al. 2008; Bowden, 2005; Sharma et al. 2005; Geller et al. 2001 ]. The clinical presentation may show a more Therapeutic Advances in Psychopharmacology 1 (5) atypical symptom spectrum than that of unipolar depression; although not diagnostic, there is consistent evidence for a greater incidence of hypersomnia, motor retardation, mood lability, weight gain and psychotic symptoms in bipolar depression [Forty et al. 2008; Bowden, 2005; Swann et al. 2005; Mitchell et al. 2001] . A particular concern, given the issue of misdiagnosis, is that more than 80% of patients with 'depression' are managed in primary care [Smith et al. 2011; NICE, 2006] but general practitioners will inevitably have less postgraduate training in mental health and there has been less research on bipolar depression in this environment. A recent twophase screening study in primary care by Smith and colleagues estimated the prevalence of undiagnosed BPAD at between 3.3% and 21.6% depending on how conservatively nonresponders and those who dropped out were treated with respect to those who completed the survey: interpreting their own results, they estimate that at least 1 in 30 patients with depression in primary care have bipolar depression [Smith et al. 2010 ]. The authors suggest that screening tools might be of utility, although the particular questionnaires, the Hypomania Checklist (HCL-32) and Bipolar Spectrum Diagnostic Scale (BSDS), had high false-positive rates and low predictive values.
Bipolar depression is pharmacologically mismanaged
The treatment of unipolar depression is substantially different from that of bipolar depression, and patients with bipolar depression who are assumed to have unipolar depression will therefore receive inappropriate therapy that not only might fail to work, but can actually also worsen their condition [Sidor and Macqueen, 2010; Bowden, 2001 Bowden, , 2005 Ghaemi et al. 2000; Altshuler et al. 1995] . Unfortunately for clinicians, however, treatment guidelines for bipolar depression are less well defined than those for mania Judd et al. 2002] . There is a lack of licensed treatments for bipolar depression. In the USA there are currently only three agents approved by the Food and Drug Administration: quetiapine monotherapy, olanzapinefluoxetine combination for the acute phase of bipolar depression, and lamotrigine for maintenance and preventive treatment [Nierenberg, 2008] . Most prescribing is therefore off licence [Frye, 2011] .
Antidepressant monotherapy
There is little evidence to support the efficacy of antidepressants as monotherapy in bipolar depression, but despite this they remain the most commonly prescribed drug in all age groups [Baldessarini et al. , 2007 , being prescribed for an estimated 50% of such patients [Sidor and Macqueen, 2010; Goldberg et al. 2009 ]. An early meta-analysis by Gijsman and colleagues did show superiority over placebo in short-term treatment, but three of the four randomized controlled trials (RCTs) included were from the 1980s, two of which tested the seldomused drugs selegiline and tranylcypromine, and the most recent one included augmentation with olanzapine in both active and placebo groups [Gijsman et al. 2004 ]. NICE's review of the evidence [NICE, 2006] found only two antidepressant RCTs rigorous enough for inclusion, of which one showed no benefit over placebo, and the other, which demonstrated superiority, again had augmentation with an antipsychotic. A meta-analysis by Sidor and MacQueen failed to show statistically significant benefit in either the acute remission or longer term recovery of patients on antidepressants compared with placebo, although there was heterogeneity in the scales and criteria used in the different studies [Sidor and MacQueen, 2010] .
Monotherapeutic antidepressant use carries the risk of manic switching [Sidor and Macqueen, 2010; Truman et al. 2007; Henry et al. 2001] , although it is also argued [Gijsman et al. 2004 ] that the absolute risk in early treatment is low. A recent meta-analysis [Ghaemi et al. 2008] suggests that antidepressant use carries a relative risk of new mania of 1.58 [95% confidence interval (CI) 0.733.42] compared with placebo and 2.37 (95% CI 1.384.05) compared with mood stabilizers, although this is debated by Sidor and MacQueen, whose meta-analysis suggests no increase in switching for selective serotonin reuptake inhibitors (SSRIs) or bupropion [Sidor and MacQueen, 2010] . However, they nuance this by arguing that cut-off criteria for switching vary: some authors have used the Young Mania Rating Scale (YMRS) to quantify affective change, but the score required to qualify as switching differs between studies, and indeed some research reports do not clearly delineate how such change was defined. Agreement on what constitutes switching remains a challenge, as does the nosological validity and long-term significance of so-called subthreshold categories. This is undoubtedly problematic for research and clinical practice, although, given the demonstrated issue of pathological mood elevation being missed, particularly in milder instances, it would seem reasonable to conclude that many patients fall into this category with detrimental longer-term outcomes. There is evidence for interclass differences in switching, with tricyclic antidepressants showing an absolute risk difference of 6.8% (95% CI 1.711.9%) compared with other classes [Gijsman et al. 2004 ]. Bupropion has a lower rate of switching than dual-acting venlafaxine and tricyclic antidepressants but shows no difference compared with SSRIs [Sidor and Macqueen, 2010] .
Thus, there is little valid research to support antidepressant use, and there is evidence that such medications increase the risk of affective switching.
Antidepressant augmentation therapy
Nemeroff and colleagues failed to show any statistically significant difference in the addition of either imipramine or paroxetine compared with placebo in subjects on lithium; indeed, subanalysis showed that in the high-lithium subgroup (serum levels >0.8 mmol/l) lithium and placebo was superior to lithium and an antidepressant [Nemeroff et al. 2001 ]. Ghaemi and colleagues undertook a meta-analysis of RCTs in which patients were followed up for more than 6 months: they found that addition of antidepressants to mood stabilizers was not superior to mood stabilizer monotherapy in longerterm management [Ghaemi et al. 2008 ]. Furthermore, whilst long-term treatment regimens that included antidepressants lowered the risk of recurrence of depression by 27% (pooled relative risk 0.73, 95% CI 0.550.97) relative to mood stabilizer monotherapy, but at the cost of a 72% increase in the risk of new episodes of mania (relative risk 1.72, 95% CI 1.232.41).
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) is a recent, large, multisite, collaborative study in BPAD that used the more naturalistic outcome measure of remaining euthymic for 8 consecutive weeks. One arm looked at bipolar depression [Sachs et al. 2007 ] in a double-blind RCT including more than 300 patients with bipolar I or II disorder who were given either a mood stabilizer and an antidepressant or a mood stabilizer and placebo. In follow up over 6 months, the addition of an antidepressant did not lead to improved outcomes, although, interestingly, there also was no increase in switching in this group, possibly due to the protection afforded by the mood stabilizer.
Thus, even when augmenting another treatment there is little evidence to support the use of antidepressants in bipolar depression.
Mood stabilizers
Although drugs such as lithium remain a mainstay of clinical treatment in bipolar depression and a first-line treatment recommended by national guidelines [Taylor et al. 2009; NICE, 2006; DSM-IV, 2000] , there have been relatively few high-quality studies of the use of lithium in its acute or long-term role [Van Lieshout and MacQueen, 2010] . Lithium can have long-term beneficial effects in all phases of bipolar depression [Bauer and Mitchner, 2004; Tondo et al. 1998 ]. A meta-analysis by Muzina and Calabrese showed that lithium is effective in reducing suicide and self-harm, but 30% of lithium-treated patients experienced breakthrough depression within 2 years [Muzina and Calabrese, 2005] . Pillhatsch and colleagues conducted a double-blind RCT to compare the efficacy and safety of adjunctive treatment with paroxetine or amitriptyline in 40 patients with BPAD who relapsed into a depressive episode during lithium maintenance therapy [Pillhatsch et al. 2010] . Although there was no comparator placebo group, patients receiving paroxetine and amitriptyline showed response rates (>50% reduction in the 21-item Hamilton Depression Rating Scale) of 76.9% and 72.2% respectively.
Lamotrigine has been advocated for bipolar depression since the mid-1990s [Calabrese et al. 2008] , although some follow-up monotherapy studies have shown ambivalent results compared with placebo. A meta-analysis of five such RCTs combining more than 1000 patients did confirmed statistically significant efficacy, albeit modest in effect size, with benefits proportional to illness severity: the pooled relative risk for response compared with placebo was 1.27 (95% CI 1.091.47) on the Hamilton Rating Scale for Depression (HRSD) and 1.22 (95% CI 1.061.41) on the MontgomeryAsberg Depression Rating Scale (MADRS), but significance for remission was obtained only on the MADRS and not the HRSD [Geddes et al. 2009 ].
Van der Loos and colleagues undertook a doubleblind RCT of lamotrigine compared with placebo in subjects already on lithium (with serum levels between 0.6 and 1.2 mmol/l), the LamLit study, which received financial support from GlaxoSmithKline, and showed a statistically significant advantage for the combination therapy in both the primary outcome of MADRS reduction and the secondary measure of response on both the MADRS and the Clinical Global Impression-Bipolar version; there was no significant difference in switching rates between the treatments [Van der Loos et al. 2010] . Interestingly, followup work by the same group added the antidepressant paroxetine to the treatment for nonresponders in both original groups. At 8 weeks this provided statistically significant benefit to those in the lithium plus placebo group but not to nonresponders in the lithium plus lamotrigine group. The authors attribute this unexpected finding to the possible catching up of the former group in relation to the potentially plateaued latter group.
Despite its common use in mood elevation, there is a lack of high-quality research on the efficacy of sodium valproate in bipolar depression. Initial RCTs [Davis et al. 2005 ] showed superiority over placebo, but the trial size was small. The evidence has appeared stronger for preventing depressive relapse Calabrese et al. 2003a Calabrese et al. , 2003b Gyulaiet al. 2003 ] than for acute management despite it being the most commonly prescribed anticonvulsant in this condition [Bond et al. 2010 ]. The BALANCE study, a large (n ¼ 330) international multisite RCT, funded in part by Sanofi-Aventis, compared valproate and lithium combination therapy with each drug in monotherapy, and showed superiority for the combination treatment over valproate monotherapy but not lithium monotherapy in preventing relapse over a 2-year period [Geddes et al. 2010 ]. This study looked at both depressive and manic relapse in bipolar I disorder, and although the authors did not set out to compare the monotherapies directly, valproate was significantly less efficacious than lithium in preventing both depressive and manic relapse. A recent systematic review and metaanalysis of four RCTs by Bond and colleagues has, however, added to the evidence in favour of this treatment, showing a relative risk of response of twice that of placebo and that of remission two thirds greater, effect sizes similar to those of quetiapine and lamotrigine [Bond et al. 2010] .
Thus, there is evidence for efficacy with lithium, lamotrigine and sodium valproate, although the study sizes have typically been small. Combination therapy with lithium plus another mood stabilizer may provide additional benefits for some.
Antipsychotics
Atypical antipsychotics have been used as adjuncts in severe unipolar depression [Joint Formulary Committee, 2011; Taylor et al. 2009 ]. Their efficacy in this regard has been argued to come from presynaptic serotonergic 5HT 2C antagonism in the prefrontal cortices, a disinhibiting effect that leads to increased release of noradrenaline and dopamine in these regions, with subsequent mood-elevating properties [Stahl, 2008] . As these drugs are also commonly used in managing the acute phase of manic and hypomanic illness, there is understandably interest in whether this class might be of benefit in bipolar depression. Antipsychotics such as quetiapine and olanzapine are being used increasingly commonly as first-line agents for many patients with bipolar depression Sachs et al. 2004; Suppes et al. 2004; Ghaemi et al. 2003; Post et al. 2003; Sajatovic et al. 2002 ].
Tohen and colleagues carried out an 8-week RCT, sponsored by Lilly, involving 833 patients with bipolar depression, randomized into either olanzapine monotherapy or an olanzapine fluoxetine combination [Tohen et al. 2003 ]. The combination was significantly more efficacious than olanzapine monotherapy and was associated with higher response and remission rates, measured on the MADRS, and lower discontinuation rates due to adverse events. The rate of switching to mania did not differ significantly between the drug combination (6.4%) and placebo (6.7%).
Quetiapine
has an active metabolite, N-desalkylquetiapine, that appears (like reboxetine) to inhibit noradrenergic reuptake pharmacodynamically and (like buspirone) to partially agonise 5HT 1A [Jensen et al. 2008 ]. The actual clinical efficacy, if any, of these additional properties is unclear, although there is some early evidence (albeit industry-sponsored) suggesting a statistically significant class superiority over other antipsychotics. Owing to its relatively favourable tolerability profile it has been used across a range of mental disorders with clinical benefit [Rowe, 2007; Calabrese et al. 2005; Adityanjee and Schulz, 2002; Suppes et al. 2010] .
Work by Calabrese and colleagues as part of the BOLDER (BipOLar DEpRession) study group, sponsored by Astra Zeneca, randomized 542 outpatients with bipolar depression with an acute major depressive episode to 8 weeks of quetiapine (300 or 600 mg/day) or placebo ]. An attraction of this study is that it included patients with bipolar I disorder (n ¼ 360) and patients with bipolar II disorder (n ¼ 182). The percentage of patients attaining remission was 52.9% in the treatment groups overall compared with the placebo rate of 28.4% (p < 0.001), with low rates of subsequent mania (3.2% and 3.9%, respectively). In addition, the rate of remission was significantly shorter for both 600 mg/day (27 days) and 300 mg/day (29 days) of quetiapine compared with placebo (65 days). The higher dose of quetiapine monotherapy (600 mg) was slightly more effective but not to a statistically significant level, and was associated with more discontinuation due to more adverse events. Post hoc secondary analyses showed greater efficacy in the bipolar I subgroup, although the authors felt numbers were too small to draw firm conclusions from this. Both doses of quetiapine were more effective than placebo in reducing suicidal thoughts at the final assessment. The reductions with quetiapine were approximately twice that with placebo. This very large study highlights some of the core difficulties in recruiting, randomizing and retaining participants: 838 patients were screened, leading to 542 recruited, of whom only 326 completed one of the trial arms. Even in a study of this size, there were insufficient participants with bipolar II disorder to draw firm conclusions, and, as will occur in all trials to remove confounders, exclusion criteria, such as comorbid substance misuse, were such as to weaken the general applicability of the results to everyday practice.
Further bipolar depression studies of similar duration have supported quetiapine's efficacy Young et al. 2010; Thase et al. 2006; Calabrese et al. 2005 ]. Suppes and colleagues recently undertook an 8-week RCT of acute depression in 418 patients with bipolar depression, and showed a statistically significant advantage to the extended release (XL) formulation (single dose, 300 mg/day) compared with placebo at weeks 1 and 8 (p < 0.001) [Suppes et al. 2010] . This longer acting formulation has the natural attraction of single daily dosing with the likelihood of improved medication concordance, although there are cost implications associated with this newer drug.
Aripiprazole, with the unique pharmacodynamic profile of a partial dopamine, 5HT 1A and 5HT 2A antagonist, has established roles in acute and maintenance treatment of manic states [Fagiolini et al. 2011] and augmenting the treatment of unipolar depression [Marcus et al. 2008 ]. However, it has shown a lack of efficacy in both acute management and maintenance treatment of bipolar depression . A clinical review by Yatham [2011] highlighted some improvement over placebo in the initial reduction of depressive symptoms, but not to statistically significant levels by the trial endpoints, and there was no reduction in depressive relapse rates.
Thus, there is good evidence for the use of olanzapine and quetiapine but no clear role for aripiprazole. There is growing evidence for quetiapine XL, although this might also reflect bias because the trials were sponsored by industry.
Conclusion
BPADs are common and debilitating, bipolar depression constituting the bulk of the psychosocial burden for patients. Bipolar depression can be difficult to diagnose and the evidence suggests that a significant number of patients in primary and secondary care remain mislabelled as having unipolar depression. This can lead to protracted periods before the correct diagnosis is made, with subsequent potential worsening disability and, indeed, iatrogenic deterioration from inappropriate treatments. There is an interesting disconnect between this and an apparent rapid rise in the rates of diagnosis of BPADs in clinical practice [Moreno et al. 2007] , and there is popular media concern about overdiagnosis and the alleged influence of celebrity culture on self-diagnosis [Chan and Sireling, 2010] .
A core pharmacological problem is our inadequate understanding of the neurobiology of bipolar illnesses. There is no clear corresponding neurotransmitter system or agreed pathway of dysfunction to model and therapeutically target, as occurs in unipolar depression and schizophrenia, although such theories are themselves heavily criticised and are fundamentally simplifications of more complex biological processes. Treatment has arisen largely serendipitously and haphazardly through the appropriation of medications used to treat epilepsy, unipolar depression and, more recently, schizophrenia. As is so often the case in psychopharmacology, backward engineering of the mechanism of action has been used to try to understand both the drugs' efficacies and any underlying dysfunction. In such a scenario, our current pharmacological reality, it is perhaps understandable that our initial attempts to treat bipolar depression were based on unipolar models and that the current therapeutic arsenal is often inadequate. Nevertheless, the pharmacological reverse engineering of existing medications and molecular biology are opening up better understanding of intracellular secondary messenger systems and putative dysfunctional enzymatic components, such as inositol monophosphatase (IMPase) and glycogen synthase kinase 3 (GSK-3), that might prove more efficacious future targets for treatment [O'Brien and Klein, 2009] . The time and cost of the development of such agents will be enormous, but until this happens there is no reason why clinical practice should not follow the best current evidence.
Although there is some conflict in the literature about appropriate pharmacological treatment and a lack of clear and consistent guidelines, several clear themes emerge. Although antidepressants are by far the most commonly prescribed drug class for such patients, there is no good evidence for their use in monotherapy and very little to support their use to augment other treatments beyond the olanzapinefluoxetine combination. In both acute and longer-term work, there is growing evidence for both mood stabilizers and antipsychotics, and within these classes lamotrigine and quetiapine respectively are showing statistically superior efficacy.
Further work is needed: better clinical guidance and psychoeducation of both patients and clinicians of this serious but treatable condition are required. Furthermore, there is a need for more RCTs in this area, particularly covering the areas of bipolar II disorder and longer-term treatment, which have to date received less attention. Finally, whilst most trials have compared an active drug with placebo, direct comparative trials between postulated treatments are needed.
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